乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ECTRIMS

<乌鸦传媒>New Evidence Sheds Light on Stem Cell Transplantation for Progressive MS

Disability, relapses no better than disease-modifying drug

<乌鸦传媒>No Excess Pregnancy, Infant Risks With Ocrelizumab for MS

Major congenital anomalies, other adverse outcomes were rare

<乌鸦传媒>Frequent MRI May Spot Active Secondary Progressive MS More Quickly

"If you rely on having a clinical relapse, you may wait a long time"

<乌鸦传媒>COVID Vaccine Response Varies With MS Treatment Type

How this relates to infection outcomes or risk of infecting others is unknown

<乌鸦传媒>Quitting Smoking Tied to Slower Motor Decline in Multiple Sclerosis

Analysis suggests smoking cessation has benefits in MS

<乌鸦传媒>Slowly Expanding Lesions in MS Reduced With BTK Inhibitor

Evobrutinib shows effect on marker of chronic inflammation

<乌鸦传媒>Virtual Care May Help Multiple Sclerosis Patients Even After the Pandemic

Early study paves the way to look at how telehealth may fit into MS care

<乌鸦传媒>Novel Anti-CD20 Drug Shows Promise in Relapsing MS

Ublituximab bests teriflunomide in head-to-head phase III trials

<乌鸦传媒>Some MS Drugs Linked With Worse COVID-19 Outcomes

Registry data looks at risks of hospitalization, ICU admission, ventilation

<乌鸦传媒>COVID-19 Hits Black MS Patients Hard

COViMS registry gives first look at outcomes among North American patients

<乌鸦传媒>Masitinib Shows Positive Signs in Progressive MS

Tyrosine kinase inhibitor targets innate immune system

<乌鸦传媒>Depression, Suicidal Thoughts Prevalent in MS

Burden equally high in relapsing-remitting and progressive multiple sclerosis

<乌鸦传媒>Can Tau Predict Early MS Disability?

Multiple sclerosis patients with higher baseline tau had worse prognosis, longitudinal study shows

<乌鸦传媒>Serum NfL Levels May Indicate MS Prodromal Phase

Study shows elevated neurofilament light levels 6 years before MS onset

<乌鸦传媒>Ofatumumab Cuts MS Relapse Rates, New Brain Lesions

Anti-CD20 monoclonal antibody poised to take on ocrelizumab

<乌鸦传媒>Ponesimod Bests Aubagio in Head-to-Head MS Trial

Investigational drug reduces annual relapse rate, shows effects on fatigue

<乌鸦传媒>IL-6 Inhibitor Cuts NMO Relapse Rates

Satralizumab reduces attacks in neuromyelitis optica spectrum disorder

<乌鸦传媒>Anti-Inflammatory Drug May Offer Benefit in Progressive MS

Ibudilast seems to diminish brain volume loss

<乌鸦传媒>Strike Three for Laquinimod in Relapsing MS

Switching endpoints for third phase III trial didn't help

<乌鸦传媒>Getting a Handle on Benign MS

Prevalence varies by definition; agreed that disease progression varies widely

<乌鸦传媒>Vaccines Tied to Relapses in Neuromyelitis Optica

Retrospective review finds protective factor in immunotherapy

<乌鸦传媒>Revised McDonald Diagnostic Criteria Revealed

Recommends using OCBs, both symptomatic and asymptomatic lesions to diagnose MS

<乌鸦传媒>European MS Guidance Taking Shape

ECTRIMS teases the first-ever MS drug guideline

<乌鸦传媒>Remyelinating Drug Flops in MS

Large placebo response, 'inverted U-shaped' dose-response in phase II trial

<乌鸦传媒>Registry Data: Lemtrada More Effective than Competing MS Tx

Better than fingolimod or interferon; comparable to natalizumab

<乌鸦传媒>New Ampyra Trial Bolsters MS Efficacy Claims

Walking ability, as reported by patients, significantly improved

<乌鸦传媒>Fluoxetine Flops as Progressive MS Therapy

Trial may have been underpowered to detect a benefit

<乌鸦传媒>Rituximab Bests MS Drugs in Swedish Registry

Rituximab offered drug survival advantage over fingolimod, natalizumab

<乌鸦传媒>HIV Drug Fails in Small MS Trial

Casts doubt on novel theory of MS etiology

<乌鸦传媒>Tysabri vs. Gilenya: Studies Conflict on Which Is Superior

Is natalizumab better than fingolimod? Flip a coin

<乌鸦传媒>Lemtrada Efficacy Persists Years after Last Dose

Most patients' responses lasted through 5-year follow-up

<乌鸦传媒>Skull Size Tied to Disability Risk in MS

BOSTON -- Multiple sclerosis patients with larger intracranial volumes -- a measure of their lifetime maximal brain size -- scored better on cognition and physical function tests than those with smaller skull sizes.

<乌鸦传媒>Multiple Sclerosis Risk Tied to Some OCs

BOSTON -- Women using combined oral contraceptives containing norethindrone or levonorgestrel were substantially more likely to develop multiple sclerosis than those not on "The Pill."

<乌鸦传媒>Generic Copaxone for MS Passes Clinical Test

BOSTON -- A copycat version of the multiple sclerosis drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a head-to-head trial, paving the way for it to win regulatory approval as a generic drug.

<乌鸦传媒>Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry

BOSTON -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.

<乌鸦传媒>Repeat Botox OK for Urinary Incontinence in MS Patients

COPENHAGEN -- Long-term treatment with serial onabotulinum toxin A (Botox) of urinary incontinence among multiple sclerosis (MS) patients appeared to be safe and effective, researchers reported here.